Abstract:Abstract Background: PALB2 (Partner and Localizer of BRCA2) is a breast cancer predisposition gene, which plays a critical role in homologous recombination via interacting with BRCA1/2 and RAD51 when DNA break. However, the clinical relevance of PALB2 germline mutations in Chinese breast cancer patients remains unknown. We attempted to illustrate the full prevalence and spectrum of PALB2 germline mutations in Chinese breast cancer population, and to investigate the clinical outcomes of PALB2 germline mutations. Patients and methods: A total of 21216 unselected breast cancer patients were enrolled from multiple clinical centers in China. After evaluation of the DNA quality and clinical information, 16501 eligible BRCA1/2-negative breast cancer patients were analyzed. A group of 5890 Chinese women without cancer was enrolled as healthy controls. PALB2 screening was based on next-generation sequencing, by screening complete coding sequence and intron-exon boundaries of PALB2. Clinical information was synchronously collected. Results: The 79 PALB2 deleterious germline mutations included 25 nonsense mutations, 47 frameshift mutations, and 7 splicing mutations. The hotspot region for PALB2 mutations was exon4. A total of 41 novel mutations were identified in PALB2. Among the 16501 BRCA1/2-negative breast cancer patients and 5890 healthy women, PALB2 deleterious mutation carriers account for 0.97% (n=160) and 0.19% (n=11) separately. PALB2 mutations were significantly associated with increased breast cancer risk (OR: 5.23, 95% CI 2.89-9.49; P<0.0001), and especially in women aged 30 or younger (OR: 11.97, 95% CI 3.76-34.39; P<0.0001). PALB2 mutation carriers were significantly more likely to be triple negative breast cancers and have bigger tumors, positive axillary lymph nodes, bilateral breast cancers, family history of breast and/or ovarian cancer and family history of any other cancer, than noncarriers. Conclusions: The PALB2 mutations confer a moderately increased breast cancer risk in women, but relatively highly increased breast cancer risk in those aged 30 or younger. PALB2 mutation status is associated with distinct clinical characteristics in breast cancer. Key words:PALB2, breast cancer, germline mutations, next-generation sequencing Citation Format: Jiaojiao Zhou, Honglian Wang, Fangmeng Fu, Zhanwen Li, Yun Liu, Qingjian Feng, Weizhu Wu, Hongxia Wang, Chuan Wang, Yiding Chen. Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-03.

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient

Functional Analysis of Patient-Derived PALB2 Missense Variants of Uncertain Significance.

Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers

A Synergetic Effect of BARD1 Mutations on Tumorigenesis

Identified Potential Pathogenic Variants of BARD1 in 1449 Chinese High-Risk Breast Cancer Patients.

Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis

Abstract P2-09-03: Spectrum, Prevalence and Clinical Outcomes of Germline Mutations in PALB2 Genes in 16501 Unselected BRCA1/2-negative Breast Cancer Patients: A Multi-Center Analysis

Case Report: Identification Pathogenic Abnormal Splicing of BBS1 Causing Bardet–Biedl Syndrome Type I (BBS1) Due to Missense Mutation

Bioinformatics Analysis of Expression and Alterations of BARD1 in Breast Cancer.

Functional Assessment of Missense Variants of Uncertain Significance in the Cancer Susceptibility Gene PALB2

Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain ( BARD1 ) gene are associated with breast cancer susceptibility: a case-control analysis

53BP1 Loss Rescues Embryonic Lethality but Not Genomic Instability of BRCA1 Total Knockout Mice

Functional analysis of BRCT missense mutations in BRCA1 -mutated Chinese Han familial breast cancer.

Genetic and Functional Studies of Genes That Regulate DNA-Damage-Induced Cell Death

Functional Polymorphisms in BARD1 Association with Neuroblastoma in a Regional Han Chinese Population

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma

CRL4-DCAF8L2 E3 Ligase Promotes Ubiquitination and Degradation of BARD1

RNF19A-mediated Ubiquitination of BARD1 Prevents BRCA1/BARD1-dependent Homologous Recombination

Identification of a novel heterozygous germline <i>RAD52</i> missense mutation in a patient with gallbladder carcinoma A case report

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer